The global real-time PCR, digital PCR, and end-point PCR market size was valued at USD 10.58 billion in 2025 and is expected to reach USD 21.31 billion by 2033, growing at a CAGR of 9.2% from 2026 to 2033. Market growth is driven by the rising prevalence of infectious diseases and cancer, increasing demand for early and accurate diagnostics, and the growing adoption of precision medicine.
Technological advancements such as multiplex PCR, digital PCR for high sensitivity, are further accelerating adoption. According to a CDC report December 2025, congenital heart defects affect approximately 1% of births annually in the U.S., highlighting the growing need for prenatal genetic testing. PCR technologies enable early detection of genetic variations, supporting timely diagnosis and treatment decisions.
The growing incidence of sexually transmitted infections (STIs) such as HIV and HPV, along with rising cases of chronic, infectious, and genetic disorders, including Alzheimer’s disease, Streptococcal infections, Turner syndrome, and Parkinson’s disease, is significantly expanding the target patient population, thereby driving the growth of real-time PCR, digital PCR, and end-point PCR markets. These conditions require highly sensitive and accurate molecular diagnostic tools for early detection and disease monitoring. For instance, according to a WHO report in July 2025, approximately 1.3 million people globally acquired HIV, highlighting the continued burden of infectious diseases. In addition, European surveillance data reported over 105,922 HIV diagnoses in 2024, with several countries observing increasing trends. Such rising disease incidence is accelerating the demand for PCR-based diagnostic solutions.
The rapid adoption of digital PCR (dPCR) for precision medicine is a key driver of market growth. Unlike conventional PCR methods, dPCR enables absolute quantification without the need for standard curves, offering ultra-high sensitivity and the ability to detect rare genetic mutations with greater accuracy. This makes it particularly valuable in oncology, infectious disease monitoring, and genetic testing, where precise detection is critical for early diagnosis and treatment selection. In addition, dPCR provides improved reproducibility and reliability, supporting its increasing use in clinical and research settings. For instance, in July 2025, Bio-Rad expanded its Droplet Digital PCR portfolio with the launch of the QX Continuum and QX700 systems, which support over 400,000 assays. This advancement reinforces dPCR’s role in precision diagnostics and accelerates its adoption across advanced healthcare applications.
Technological advancements in multiplexing and assay innovation are significantly improving the efficiency and throughput of PCR-based diagnostics, thereby driving market growth. Advanced multiplex PCR systems enable the simultaneous detection of multiple pathogens in a single test, reducing turnaround time, operational costs, and sample requirements. For instance, in November 2025, FlashDx introduced a fully automated multiplex real-time PCR system based on semi-solid phase real-time PCR (sSPRT) technology, enabling a seamless sample-to-result workflow and rapid multi-pathogen detection. In addition, a study published in January 2026 developed a multiplex RT-qPCR assay capable of detecting 18 respiratory viruses simultaneously, demonstrating high sensitivity up to 99.81% and specificity 100%, significantly improving diagnostic throughput, further enhancing diagnostic accuracy, and laboratory productivity.
Moreover, the growth of point-of-care (POC) and decentralized testing is significantly driving the PCR market, supported by increasing demand for portable, rapid, and easy-to-use diagnostic systems. Miniaturized PCR devices enable faster turnaround times and facilitate testing in clinics, airports, and remote settings, strengthening pandemic preparedness and on-site diagnostics. Simultaneously, the rising demand for high-throughput, automated systems is encouraging laboratories to adopt advanced platforms that process large sample volumes with minimal human intervention, thereby reducing errors and improving efficiency.
Technological advancements such as multiplex PCR, digital PCR for high sensitivity, are further accelerating adoption. According to a CDC report December 2025, congenital heart defects affect approximately 1% of births annually in the U.S., highlighting the growing need for prenatal genetic testing. PCR technologies enable early detection of genetic variations, supporting timely diagnosis and treatment decisions.
The growing incidence of sexually transmitted infections (STIs) such as HIV and HPV, along with rising cases of chronic, infectious, and genetic disorders, including Alzheimer’s disease, Streptococcal infections, Turner syndrome, and Parkinson’s disease, is significantly expanding the target patient population, thereby driving the growth of real-time PCR, digital PCR, and end-point PCR markets. These conditions require highly sensitive and accurate molecular diagnostic tools for early detection and disease monitoring. For instance, according to a WHO report in July 2025, approximately 1.3 million people globally acquired HIV, highlighting the continued burden of infectious diseases. In addition, European surveillance data reported over 105,922 HIV diagnoses in 2024, with several countries observing increasing trends. Such rising disease incidence is accelerating the demand for PCR-based diagnostic solutions.
The rapid adoption of digital PCR (dPCR) for precision medicine is a key driver of market growth. Unlike conventional PCR methods, dPCR enables absolute quantification without the need for standard curves, offering ultra-high sensitivity and the ability to detect rare genetic mutations with greater accuracy. This makes it particularly valuable in oncology, infectious disease monitoring, and genetic testing, where precise detection is critical for early diagnosis and treatment selection. In addition, dPCR provides improved reproducibility and reliability, supporting its increasing use in clinical and research settings. For instance, in July 2025, Bio-Rad expanded its Droplet Digital PCR portfolio with the launch of the QX Continuum and QX700 systems, which support over 400,000 assays. This advancement reinforces dPCR’s role in precision diagnostics and accelerates its adoption across advanced healthcare applications.
Technological advancements in multiplexing and assay innovation are significantly improving the efficiency and throughput of PCR-based diagnostics, thereby driving market growth. Advanced multiplex PCR systems enable the simultaneous detection of multiple pathogens in a single test, reducing turnaround time, operational costs, and sample requirements. For instance, in November 2025, FlashDx introduced a fully automated multiplex real-time PCR system based on semi-solid phase real-time PCR (sSPRT) technology, enabling a seamless sample-to-result workflow and rapid multi-pathogen detection. In addition, a study published in January 2026 developed a multiplex RT-qPCR assay capable of detecting 18 respiratory viruses simultaneously, demonstrating high sensitivity up to 99.81% and specificity 100%, significantly improving diagnostic throughput, further enhancing diagnostic accuracy, and laboratory productivity.
Moreover, the growth of point-of-care (POC) and decentralized testing is significantly driving the PCR market, supported by increasing demand for portable, rapid, and easy-to-use diagnostic systems. Miniaturized PCR devices enable faster turnaround times and facilitate testing in clinics, airports, and remote settings, strengthening pandemic preparedness and on-site diagnostics. Simultaneously, the rising demand for high-throughput, automated systems is encouraging laboratories to adopt advanced platforms that process large sample volumes with minimal human intervention, thereby reducing errors and improving efficiency.
Global Real-time PCR, Digital PCR, And End-point PCR Market Report Segmentation
This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2018 to 2030. For the purpose of this report, the analyst has segmented the global real time PCR, digital PCR, and end-point PCR market report on the basis of technology, application, product, and regions.Technology Outlook (Revenue, USD Million, 2021-2033)
- Quantitative
- Consumables & Reagents
- Instruments
- Software & Services
- Digital
- Consumables & Reagents
- Instruments
- Software & Services
- End-point
- Consumables & Reagents
- Instruments
- Software & Services
Product Outlook (Revenue, USD Million, 2021-2033)
- Consumables & Reagents
- Instruments
- Software & Services
Application Outlook (Revenue, USD Million, 2021-2033)
- Clinical
- Pathogen Testing
- Oncology testing
- Blood Screening
- Liquid Biopsy
- dPCR-based Non-Invasive Prenatal Testing (NIPT)
- Others
- Research
- Stem Cell Research
- DNA Cloning & Sequencing
- Recombinant DNA Technology
- Rare Mutation Detection
- Gene Expression
- Single Cell Analysis
- Microbiome Analysis
- Copy Number Variation Analysis
- Library Quantification (NGS)
- Characterization of Low-fold Changes in mRNA and miRNA Expression.
- Species Identification
- GMO Detection
- Others
- Forensic
Regional Outlook (Revenue, USD Million, 2021-2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Real Time PCR, Digital PCR and End-Point PCR Market Variables, Trends & Scope
Chapter 4. Real Time PCR, Digital PCR and End-Point PCR Market: Technology Estimates & Trend Analysis
Chapter 5. Real-time PCR (qPCR), end point PCR, and dPCR Market Analysis, Product Scope, 2021-2033 (Revenue, USD Million)
Chapter 6. Real-time PCR (qPCR), end point PCR, and dPCR Market Analysis, Application Scope, 2021-2033 (Revenue, USD Million)
Chapter 7. Real-time PCR (qPCR), end point PCR, and dPCR Market Analysis, Regional Scope, 2021-2033 (Revenue, USD Million)
Chapter 8. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- Abbott
- Qiagen
- Bio-Rad Laboratories Inc.
- Agilent Technologies, Inc.
- Thermo Fisher Scientific, Inc.
- GE Healthcare
- bioMérieux
- F. Hoffmann-La Roche Ltd
- Fluidigm Corporation
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 120 |
| Published | April 2026 |
| Forecast Period | 2025 - 2033 |
| Estimated Market Value ( USD | $ 10.58 Billion |
| Forecasted Market Value ( USD | $ 21.31 Billion |
| Compound Annual Growth Rate | 9.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 9 |
